NORTH CHICAGO, Ill – AbbVie (ABBV) has reached a significant advancement in the development of upadacitinib (RINVOQ), a JAK inhibitor for autoimmune hair loss diseases, [Read More…]
AbbVie has finalized its acquisition of Capstan Therapeutics, gaining access to a groundbreaking in vivo tLNP CAR-T cell therapy and proprietary RNA delivery platform for B cell-mediated autoimmune diseases.
Gilead Sciences reports a successful second quarter for 2025, with total revenue climbing to $7.1 billion, driven by a 7% increase in its HIV franchise sales. Diluted EPS rose to $1.56. Following these strong results, Gilead has raised its full-year 2025 guidance, now expecting product sales between $28.3 billion and $28.7 billion.
Allogene Therapeutics, a clinical-stage biotechnology company, has selected the standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 study.
Eli Lilly and Company announced results from the long-term extension of the Phase 3 TRAILBLAZER-ALZ 2 study, demonstrating that participants treated with Kisunla (donanemab-azbt) for early symptomatic Alzheimer’s disease showed a continued slowing of decline over three years.
AstraZeneca‘s supplemental biologics license application (sBLA) for Imfinzi (durvalumab) has been approved and given priority review in the U.S. FDA for the treatment of patients with [Read More…]
Novo Nordisk reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a favorable opinion, suggesting that [Read More…]
The European Commission (EC) has granted a landmark approval for Johnson & Johnson’s DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma (SMM). This decision marks a significant shift in the treatment paradigm for this precursor to active multiple myeloma, moving away from the traditional “watch and wait” approach to proactive, early therapeutic intervention.
Genentech, a member of the Roche Group, announced Friday that the U.S. Food and Drug Administration (FDA) has rejected its application to expand the use of its cancer drug Columvi® (glofitamab-gxbm). The FDA issued a Complete Response Letter (CRL) for the supplemental Biologics License Application (sBLA), effectively declining to approve Columvi in combination with chemotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
A key takeaway from the presentation is the strong preference for the twice-yearly injection over daily oral medication among trial participants. Over 75% of those surveyed expressed a preference for the injectable option, citing increased confidence in their protection against HIV and a lower risk of missing a dose.
